Key result
Very low baseline platelet count shows no link to increased major bleeding in acute VTE.
Why the study?
Abnormal platelet count is common in acute venous thromboembolism, but its relationship with clinical outcomes remains ill-defined.
Does abnormal baseline platelet count predict major bleeding or other long-term clinical outcomes in patients with acute venous thromboembolism?
Cohort (n=991)
Yes
Does abnormal baseline platelet count predict major bleeding or other long-term clinical outcomes in patients with acute venous thromboembolism?
Effect estimate: SHR 1.23 (95% CI 0.52-2.91)
Absolute Event Rate: 36% vs 15%
p-value: p=0.636
Baseline platelet count does not have a consistent relationship with long-term clinical outcomes such as major bleeding or mortality in patients with acute VTE, although low platelet count may be associated with increased VTE recurrence.
No takes yet. Share an insight, caveat, or question.
Baseline platelet count should not guide long-term bleeding risk assessment in acute VTE; leaves open its role in recurrence.
Stuby et al. (2024) conducted a cohort in Acute venous thromboembolism (n=991). Very low baseline platelet count (< 100 G/l) vs. Normal baseline platelet count (150-450 G/l) was evaluated on Major bleeding (SHR 1.23, 95% CI 0.52-2.91, p=0.636). Very low baseline platelet count was not significantly associated with an increased long-term risk of major bleeding (SHR 1.23) compared to normal platelet count in patients with acute VTE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: